Use of Avastin drug to treat AMD queried

24 April 2012

Brits who are seeking a cheaper drug in order to overcome a main cause leading to the loss of vision have been warned about the use.

Avastin has been deemed a more cost-effective alternative to Lucentis in the treatment of wet age-related macular degeneration (AMD).

However, the drug has not been officially recognised to treat such severe eye conditions in the UK.

Despite this, the NHS in Southampton, Hampshire, the Isle of Wight and Portsmouth last year began prescribing the use of Avastin.

Pharmaceutical company Novartis has now challenged the drug's use and is seeking a judicial review of the policy to pay for Avastin on the NHS.

The company told BBC News: "It is unacceptable to put the safety of patients at risk through the widespread use of an unlicensed treatment when a licensed medicine is available."

Meanwhile, scientists at Trinity College Dublin have recently discovered a chemical which could be used as a one-off injection to form another alternative treatment to AMD.

Posted by Jeanette Royston


Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.
 

Find a treatment, test or scan available at:

or

Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.

or

Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...

Categories

Ophthalmology

© Spire Healthcare Group plc (2016)